AMENDMENTS TO THE CLAIMS

2

Please amend the claims so that they read as follows:

Claims 1-29 (Canceled).

30. (Currently Amended) The compound

and salts thereof.

- 31. (Canceled).
- 32. (Previously Presented) A composition comprising
 - (a) an active agent; and
 - (b) the compound of claim 30.
- 33. (Previously Presented) A composition as defined in claim 32, wherein said active agent is selected from the group consisting of a pharmacologic agent and a therapeutic active agent.
- 34. (Previously Presented) A composition as defined in claim 32, wherein said active agent is selected from the group consisting of a biologically active agent and a chemically active agent.
- 35. (Previously Presented) A composition as defined in claim 34, wherein said biologically active agent is selected from the group consisting of a peptide, a polysaccharide, a mucopolysaccharide, a carbohydrate, a lipid, a pesticide, and any combination thereof.
- 36. (Previously Presented) A composition as defined in claim 35, wherein said active agent comprises a peptide.

Application No.: 10/623,142 3 Docket No.: 01946/100B035-USD

37. (Previously Presented) A composition as defined in claim 35, wherein said active agent comprises a polysaccharide.

- 38. (Previously Presented) A composition as defined in claim 35, wherein said active agent comprises a mixture of mucopolysaccharides.
- 39. (Previously Presented) A composition as defined in claim 34, wherein said biologically active agent is a hormone.
- 40. (Previously Presented) A composition as defined in claim 38, wherein said mixture of mucopolysaccharides comprises heparin.
- 41. (Previously Presented) A composition as defined in claim 34, wherein said biologically active agent is selected from the group consisting of human growth hormones; bovine growth hormones; growth releasing hormones; growth hormone-releasing hormones; interferons; interleukin-I; interleukin-II; insulin; heparin, calcitonin; erythropoietin; atrial naturetic factor; antigens; monoclonal antibodies; somatostatin; adrenocorticotropin, gonadotropin releasing hormone; oxytocin; vasopressin; cromolyn sodium; vancomycin; desferrioxamine (DFO); parathyroid hormone, anti-microbials, or any combination thereof.
- 42. (Previously Presented) The composition of claim 41, wherein said biologically active agent comprises insulin.
- 43. (Previously Presented) The composition of claim 41, wherein said biologically active agent comprises heparin.
- 44. (Previously Presented) A composition as defined in claim 43, wherein said heparin comprises low molecular weight heparin.
- 45. (Previously Presented) The composition of claim 41, wherein said biologically active agent comprises calcitonin.

46. (Previously Presented) A composition as defined in claim 41, wherein said biologically active agent comprises human growth hormone.

- 47. (Previously Presented) The composition of claim 41, wherein said biologically active agent comprises parathyroid hormone.
- 48. (Previously Presented) A dosage unit form comprising a composition as defined in claim 32; and
 - (a) an excipient
 - (b) a diluent,
 - (c) a disintegrant,
 - (d) a lubricant,
 - (e) a plasticizer,
 - (f) a colorant,
 - (g) a dosing vehicle, or
 - (h) any combination thereof.
- 49. (Previously Presented) A dosage unit form according to claim 48, comprising a tablet, a capsule, or a liquid.
- 50. (Previously Presented) A dosage unit form according to claim 49, consisting of a tablet.
- 51. (Previously Presented) A dosage unit form according to claim 49, consisting of a capsule.
- 52. (Previously Presented) The dosage unit form of claim 48, wherein said active agent is selected from the group consisting of a biologically active agent and a chemically active agent.
- 53. (Previously Presented) The dosage unit form of claim 52, wherein said biologically active agent is selected from the group consisting of a peptide, a

polysaccharide, a mucopolysaccharide, a carbohydrate, a lipid, a pesticide, and any combination thereof.

- 54. (Previously Presented) The dosage unit form of claim 53, wherein said biologically active agent comprises a polysaccharide.
- 55. (Previously Presented) The dosage unit form of claim 53, wherein said biologically active agent comprises a peptide.
- 56. (Previously Presented) The dosage unit form of claim 53, wherein said biologically active agent comprises a mixture of mucopolysaccharides.
- 57. (Previously Presented) The dosage unit form of claim 56, wherein said mixture of mucopolysaccharides comprises heparin.
- 58. (Previously Presented) The dosage unit form of claim 52, wherein said biologically active agent is selected from the group consisting of human growth hormones; bovine growth hormones; growth releasing hormones; growth hormone-releasing hormones; interferons; interleukin-II; insulin; heparin, calcitonin; erythropoietin; atrial naturetic factor; antigens; monoclonal antibodies; somatostatin; adrenocorticotropin, gonadotropin releasing hormone; oxytocin; vasopressin; cromolyn sodium; vancomycin; desferrioxamine (DFO); parathyroid hormone, anti-microbials, or any combination thereof.
- 59. (Previously Presented) The dosage unit form of claim 58, wherein said biologically active agent comprises heparin.
- 60. (Previously Presented) The dosage unit form of claim 59, wherein said heparin comprises low molecular weight heparin.
- 61. (Previously Presented) The dosage unit form of claim 58, wherein said biologically active agent comprises insulin.

Application No.: 10/623,142 6 Docket No.: 01946/100B035-USD

62. (Previously Presented) The dosage unit form of claim 58, wherein said biologically active agent comprises parathyroid hormones.

- 63. (Previously Presented) The dosage unit form of claim 58, wherein said biologically active agent comprises calcitonin.
- 64. (Previously Presented) The dosage unit form of claim 58, wherein said biologically active agent comprises human growth hormone.
- 65. (Previously Presented) A method for preparing a composition, said method comprising mixing:
 - (a) at least one biologically active agent;
 - (b) at least one compound as defined in claim 30; and
 - (c) optionally a dosing vehicle.
- 66. (Previously Presented) A method as defined in claim 65, wherein said biologically active agent comprises a peptide.
- 67. (Previously Presented) A method as defined in claim 65, wherein said biologically active agent comprises polysaccharide.
- 68. (Previously Presented) A method as defined in claim 65, wherein said polysaccharide comprises a mixture of muco-polysaccharides.
- 69. (Previously Presented) The method of claim 65, wherein said biologically active agent is selected from the group consisting of human growth hormones; bovine growth hormones; growth releasing hormones; growth hormone-releasing hormones; interferons; interleukin-I; interleukin-II; insulin; heparin, calcitonin; erythropoietin; atrial naturetic factor; antigens; monoclonal antibodies; somatostatin; adrenocorticotropin, gonadotropin releasing hormone; oxytocin; vasopressin; cromolyn sodium; vancomycin;

desferrioxamine (DFO); parathyroid hormone, anti-microbials, or any combination thereof.

- 70. (Previously Presented) A method of administering a biologically-active agent to an animal in need of said agent, said method comprising administering to said animal a composition as defined in claim 32.
- 71. (Previously Presented) A method for administering a biologically-active agent as defined in claim 70, wherein said administration is oral.
- 72. (Previously Presented) A method for administering a biologically-active agent as defined in claim 70, wherein said animal is a mammal.
- 73. (Previously Presented) A method for administering a biologically-active agent as defined in claim 72, wherein said mammal is a human.
- 74. (Previously Presented) A method for administering a biologically-active agent as defined in claim 70, wherein said composition is a solid.
- 75. (Previously Presented) A method for administering a biologically-active agent as defined in claim 74, wherein said composition is a tablet or capsule.
- 76. (Previously Presented) A method for administering a biologically-active agent to an animal in need of said agent, said method comprising administering orally to said animal a composition as defined in claim 36.
- 77. (Previously Presented) A method for administering a biologically-active agent to an animal in need of said agent, said method comprising administering orally to said animal a composition as defined in claim 38.
- 78. (Previously Presented) A method for administering a biologically-active agent to an animal in need of said agent, said method comprising administering orally to said animal a composition as defined in claim 40.

Application No.: 10/623,142 8 Docket No.: 01946/100B035-USD

79. (Previously Presented) A method for administering a biologically-active agent to an animal in need of said agent, said method comprising administering orally to said animal a composition as defined in claim 42.

- 80. (Previously Presented) A method for administering a biologically-active agent to an animal in need of said agent, said method comprising administering orally to said animal a composition as defined in claim 43.
- 81. (Previously Presented) A method for administering a biologically-active agent to an animal in need of said agent, said method comprising administering orally to said animal a composition as defined in claim 44.
- 82. (Previously Presented) A method for administering a biologically-active agent to an animal in need of said agent, said method comprising administering orally to said animal a composition as defined in claim 45.
- 83. (Previously Presented) A method for administering a biologically-active agent to an animal in need of said agent, said method comprising administering orally to said animal a composition as defined in claim 46.
- 84. (Previously Presented) A method for administering a biologically-active agent to an animal in need of said agent, said method comprising administering orally to said animal a composition as defined in claim 47.